X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1010) 1010
humans (965) 965
male (598) 598
female (576) 576
oncology (521) 521
aged (504) 504
hematology (496) 496
middle aged (490) 490
azacitidine - therapeutic use (477) 477
azacitidine (447) 447
azacitidine - analogs & derivatives (436) 436
azacitidine - adverse effects (405) 405
azacitidine - administration & dosage (338) 338
cancer (335) 335
myelodysplastic syndromes - drug therapy (333) 333
adult (322) 322
treatment outcome (300) 300
decitabine (292) 292
dna methylation (288) 288
myelodysplastic syndromes (281) 281
antimetabolites, antineoplastic - therapeutic use (267) 267
aged, 80 and over (263) 263
azacitidine - pharmacology (241) 241
leukemia, myeloid, acute - drug therapy (238) 238
acute myeloid-leukemia (225) 225
myelodysplastic syndrome (221) 221
leukemia (213) 213
antimetabolites, antineoplastic - adverse effects (192) 192
methylation (177) 177
dna methylation - drug effects (171) 171
chemotherapy (165) 165
acute myeloid leukemia (162) 162
prognosis (160) 160
care and treatment (153) 153
animals (149) 149
antineoplastic combined chemotherapy protocols - therapeutic use (145) 145
conventional care regimens (128) 128
analysis (124) 124
research (124) 124
antimetabolites, antineoplastic - administration & dosage (123) 123
therapy (123) 123
transplantation (117) 117
hematology, oncology and palliative medicine (116) 116
antineoplastic agents (115) 115
myelodysplastic syndromes - mortality (115) 115
antimitotic agents (112) 112
5-azacytidine (111) 111
drug administration schedule (109) 109
medicine & public health (109) 109
leukemia, myeloid, acute - mortality (104) 104
survival (102) 102
aml (101) 101
retrospective studies (100) 100
epigenetics (99) 99
older patients (98) 98
antineoplastic combined chemotherapy protocols - adverse effects (97) 97
mds (96) 96
article (95) 95
phase-iii (94) 94
survival analysis (94) 94
pharmacology & pharmacy (91) 91
stem cells (91) 91
antineoplastic agents - therapeutic use (90) 90
remission induction (90) 90
myelodysplastic syndromes - genetics (87) 87
dose-response relationship, drug (86) 86
myelodysplastic syndromes - therapy (84) 84
adolescent (83) 83
5-aza-2'-deoxycytidine (81) 81
cell line, tumor (81) 81
health aspects (81) 81
risk factors (81) 81
dna (80) 80
hypomethylating agents (80) 80
elderly-patients (78) 78
leukemia, myeloid, acute - genetics (78) 78
myelodysplastic syndromes - diagnosis (78) 78
stem-cell transplantation (77) 77
abridged index medicus (75) 75
drug therapy (75) 75
gene expression (75) 75
acute myelogenous leukemia (74) 74
mice (74) 74
myelodysplastic syndromes - pathology (73) 73
young adult (73) 73
expression (72) 72
international working group (72) 72
intensive chemotherapy (70) 70
patients (69) 69
classification (68) 68
leukemia, myeloid, acute - pathology (67) 67
disease-free survival (65) 65
antineoplastic agents - adverse effects (64) 64
clinical trials as topic (63) 63
scoring system (63) 63
antimetabolites, antineoplastic - pharmacology (62) 62
hematopoietic stem cells (62) 62
survival rate (62) 62
medical research (61) 61
response criteria (61) 61
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1161) 1161
Chinese (4) 4
French (4) 4
Spanish (3) 3
Japanese (2) 2
German (1) 1
Hebrew (1) 1
Korean (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet Oncology, ISSN 1470-2045, 02/2018, Volume 19, Issue 2, pp. 216 - 228
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2012, Volume 30, Issue 21, pp. 2670 - 2677
Journal Article
Blood, ISSN 0006-4971, 10/2007, Volume 110, Issue 7, pp. 2302 - 2308
Journal Article
Cancer Discovery, ISSN 2159-8274, 12/2011, Volume 1, Issue 7, pp. 598 - 607
Journal Article
Blood, ISSN 0006-4971, 09/2018, Volume 132, Issue 11, pp. 1125 - 1133
Treatment of acute myeloid leukemia (AML) among the elderly is challenging because of intolerance of intensive therapy and therapy-resistant biology.... 
GEMTUZUMAB OZOGAMICIN MYLOTARG | NEWLY-DIAGNOSED AML | THERAPY | OLDER PATIENTS | EFFICACY | LOW-DOSE CYTARABINE | OPEN-LABEL | ACUTE MYELOID-LEUKEMIA | AZACITIDINE | COMBINATION | HEMATOLOGY | Azacitidine - adverse effects | Decitabine - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Pyrroles - pharmacokinetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Neoplasm, Residual | Antibodies, Monoclonal, Humanized - administration & dosage | Antibodies, Monoclonal, Humanized - pharmacokinetics | Pyrroles - administration & dosage | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Pyrroles - adverse effects | Female | Sialic Acid Binding Ig-like Lectin 3 | Decitabine - pharmacokinetics | Azacitidine - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Azacitidine - pharmacokinetics | Survival Rate | Benzodiazepines - pharmacokinetics | Leukemia, Myeloid, Acute - blood | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Benzodiazepines - administration & dosage | Aged | Benzodiazepines - adverse effects | Decitabine - adverse effects | Index Medicus | Abridged Index Medicus | Clinical Trials and Observations
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2016, Volume 375, Issue 21, pp. 2023 - 2036
Journal Article
British Journal of Haematology, ISSN 0007-1048, 11/2014, Volume 167, Issue 3, pp. 356 - 365
To test the safety and activity of 5‐aza‐2′‐deoxycytidine (decitabine) in patients with relapsed/refractory acute lymphocytic leukaemia ( ALL ), we conducted a... 
clinical trial | decitabine | precursor cell lymphoblastic leukaemia‐Lymphoma | DNA | methylation | DNA methylation | Clinical trial | Decitabine | Precursor cell lymphoblastic leukaemia-Lymphoma | precursor cell lymphoblastic leukaemia-Lymphoma | MECHANISMS | COMBINATION | CHEMOTHERAPY | EPIGENETICS | ACUTE LYMPHOBLASTIC-LEUKEMIA | ABERRANT DNA METHYLATION | DISEASE | MYELOID-LEUKEMIA | HEMATOLOGY | PHASE-I | P57KIP2 | Recurrence | Azacitidine - adverse effects | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Dexamethasone - adverse effects | Male | Cytarabine - adverse effects | Cyclophosphamide - adverse effects | DNA, Neoplasm - chemistry | Antimetabolites, Antineoplastic - administration & dosage | Young Adult | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Hyperglycemia - chemically induced | Vincristine - administration & dosage | Adult | Female | Child | Chemical and Drug Induced Liver Injury - etiology | Azacitidine - administration & dosage | Doxorubicin - administration & dosage | Dexamethasone - administration & dosage | Drug Administration Schedule | Kaplan-Meier Estimate | Azacitidine - analogs & derivatives | Remission Induction | Cytarabine - administration & dosage | Methotrexate - adverse effects | Antimetabolites, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Bone Marrow - pathology | Adolescent | Antimetabolites, Antineoplastic - adverse effects | Vincristine - adverse effects | Methotrexate - administration & dosage | Aged | Infusions, Intravenous | DNA Methylation - drug effects | Doxorubicin - adverse effects | Gastrointestinal Diseases - chemically induced | Azacitidine - therapeutic use | Index Medicus | DNA Methylation | Precursor Cell Lymphoblastic Leukaemia-Lymphoma | Clinical Trial
Journal Article
Cancer Research, ISSN 0008-5472, 05/2012, Volume 72, Issue 9, pp. 2197 - 2205
Journal Article
British Journal of Haematology, ISSN 0007-1048, 02/2016, Volume 172, Issue 3, pp. 384 - 391
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2011, Volume 29, Issue 18, pp. 2521 - 2527
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 4, pp. 496 - 508
Journal Article